524 related articles for article (PubMed ID: 34036375)
1. lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
Cao Y; Chai W; Wang Y; Tang D; Shao D; Song H; Long J
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036375
[TBL] [Abstract][Full Text] [Related]
2. EZH2-regulated PARP-1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide.
Liang Q; Wang B; Zhang C; Song C; Wang J; Sun W; Jiang L; Lin J
Curr Cancer Drug Targets; 2024; 24(3):328-339. PubMed ID: 37594167
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2.
Niu Y; Ma F; Huang W; Fang S; Li M; Wei T; Guo L
Mol Cancer; 2017 Jan; 16(1):5. PubMed ID: 28069000
[TBL] [Abstract][Full Text] [Related]
4. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
5. Curcumol inhibits malignant biological behaviors and TMZ-resistance in glioma cells by inhibiting long noncoding RNA FOXD2-As1-promoted EZH2 activation.
Lv X; Sun J; Hu L; Qian Y; Fan C; Tian N
Aging (Albany NY); 2021 Nov; 13(21):24101-24116. PubMed ID: 34739394
[TBL] [Abstract][Full Text] [Related]
6. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Li C; Feng S; Chen L
Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
[TBL] [Abstract][Full Text] [Related]
7. The Lncrna-TUG1/EZH2 Axis Promotes Pancreatic Cancer Cell Proliferation, Migration and EMT Phenotype Formation Through Sponging Mir-382.
Zhao L; Sun H; Kong H; Chen Z; Chen B; Zhou M
Cell Physiol Biochem; 2017; 42(6):2145-2158. PubMed ID: 28813705
[TBL] [Abstract][Full Text] [Related]
8. TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2.
Li Q; Song W; Wang J
Biomed Pharmacother; 2019 Jan; 109():1793-1801. PubMed ID: 30551433
[TBL] [Abstract][Full Text] [Related]
9. TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via miR-144-3p.
Cao J; Han X; Qi X; Jin X; Li X
Int J Oncol; 2017 Oct; 51(4):1115-1123. PubMed ID: 28902349
[TBL] [Abstract][Full Text] [Related]
10. Long Noncoding RNA KCNQ1OT1 Confers Gliomas Resistance to Temozolomide and Enhances Cell Growth by Retrieving PIM1 From miR-761.
Wang W; Han S; Gao W; Feng Y; Li K; Wu D
Cell Mol Neurobiol; 2022 Apr; 42(3):695-708. PubMed ID: 32897512
[TBL] [Abstract][Full Text] [Related]
11. A positive feedback loop of lncRNA-RMRP/ZNRF3 axis and Wnt/β-catenin signaling regulates the progression and temozolomide resistance in glioma.
Liu T; Hu J; Han B; Tan S; Jia W; Xin Y
Cell Death Dis; 2021 Oct; 12(11):952. PubMed ID: 34657141
[TBL] [Abstract][Full Text] [Related]
12. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells.
Mazor G; Levin L; Picard D; Ahmadov U; Carén H; Borkhardt A; Reifenberger G; Leprivier G; Remke M; Rotblat B
Cell Death Dis; 2019 Mar; 10(3):246. PubMed ID: 30867410
[TBL] [Abstract][Full Text] [Related]
13. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y
Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732
[TBL] [Abstract][Full Text] [Related]
14. LncRNA-XIST interacts with
Du P; Zhao H; Peng R; Liu Q; Yuan J; Peng G; Liao Y
Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28831025
[TBL] [Abstract][Full Text] [Related]
15. EZH2-mediated α-actin methylation needs lncRNA TUG1, and promotes the cortex cytoskeleton formation in VSMCs.
Chen R; Kong P; Zhang F; Shu YN; Nie X; Dong LH; Lin YL; Xie XL; Zhao LL; Zhang XJ; Han M
Gene; 2017 Jun; 616():52-57. PubMed ID: 28344045
[TBL] [Abstract][Full Text] [Related]
16. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
17. LncRNA ANCR promotes glioma cells invasion, migration, proliferation and inhibits apoptosis via interacting with EZH2 and repressing PTEN expression.
Cheng C; Dong Y; Ru X; Xia Y; Ji Y
Cancer Gene Ther; 2021 Sep; 28(9):1025-1034. PubMed ID: 33293663
[TBL] [Abstract][Full Text] [Related]
18. Long intergenic noncoding RNA 00021 promotes glioblastoma temozolomide resistance by epigenetically silencing p21 through Notch pathway.
Zhang S; Guo S; Liang C; Lian M
IUBMB Life; 2020 Aug; 72(8):1747-1756. PubMed ID: 32449315
[TBL] [Abstract][Full Text] [Related]
19. NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/
Chen M; Cheng Y; Yuan Z; Wang F; Yang L; Zhao H
Cancer Biother Radiopharm; 2020 Mar; 35(2):101-108. PubMed ID: 31750728
[No Abstract] [Full Text] [Related]
20. EZH2-mediated H3K27me3 enrichment on the lncRNA MEG3 promoter regulates the growth and metastasis of glioma cells by regulating miR-21-3p.
Qin WX; Shi Y; Zhu D; Li YP; Chen YH; Cui J; Cui GY; Pan JX; Ren ZY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3204-3214. PubMed ID: 32271438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
